| Name | Title | Contact Details |
|---|
Acumed Medical is a Saint Louis, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
SunTech Medical is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.
Volpara Health Technologies Limited is a leading provider of breast imaging analytics and analysis products that improve clinical decision-making and the early detection of breast cancer. Every day, Volpara software helps clinicians better understand their patients and administrators better understand their practices. Volpara Health Technologies Limited (formerly Matakina Technology Limited) is a research, development, and manufacturing company based in Wellington, New Zealand. With a diverse research team led by internationally recognized experts in medical physics, as well as proprietary medical imaging technology covered by multiple patents and trademarks, we apply science to the solving of clinical problems around the world. Volpara Health Technologies Limited holds certification to ISO13485 and is a US FDA–registered establishment whose products are listed accordingly. In addition, our products hold CE Marking under European Medical Device Directive 93/42/EEC. Volpara Solutions Limited is our wholly owned sales and marketing subsidiary.
Alpha Imaging is a Willoughby, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
At T2 Biosystems, we are united in our mission: to improve patient outcomes, lower mortality rates and reduce the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. By leveraging the power of our innovative and proprietary T2 Magnetic Resonance (T2MR) platform, T2 Biosystems’ diagnostics are designed to provide faster, easier and more accurate results than traditional methodologies. T2 Biosystems is currently targeting a range of critically underserved healthcare conditions, focusing initially on those for which a rapid diagnosis will serve an important dual role – saving lives and reducing costs. Our T2Candida Panel tackles sepsis and is the first FDA-cleared diagnostic panel requiring no blood culture – delivering more accurate results in hours versus days. Other ongoing development efforts include bacterial and hemostasis panels, as well as a Lyme disease partnership with Canon Life Sciences. Over 100 studies published in peer-reviewed journals have featured T2MR technology in a breadth of applications, including the direct detection and measurement of targets in various sample types, such as whole blood, plasma, serum, saliva, sputum and urine. With limits of detection as low as 1 CFU/mL, we believe T2MR technology will drive the next generation of diagnostics.